Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00001595
Other study ID # 970076
Secondary ID 97-CH-0076
Status Recruiting
Phase
First received
Last updated
Start date April 21, 1997

Study information

Verified date December 15, 2023
Source National Institutes of Health Clinical Center (CC)
Contact Samah M Agabein
Phone (301) 451-7615
Email samah.agabein@nih.gov
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood. The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present study serves as a (i) screening/training, and, (ii) a research protocol. As a screening and training study, this protocol allows our Institute to admit children with tumors of the hypothalamic-pituitary unit to the pediatric endocrine clinics and wards of the NIH Clinical Center for the purposes of (i)<TAB>training our fellows and students in the identification of genetic defects associated with pituitary tumor formation, and (ii)<TAB>teaching our fellows and students the recognition, management and complications of pituitary tumors As a research study, this protocol aims at (i)<TAB>developing new clinical studies for the recognition and therapy of pituitary tumors; as an example, two new studies have emerged within the context of this protocol: (a) investigation of a new research magnetic resonance imaging (MRI) tool and its usefulness in the identification of pituitary tumors, and (b) investigation of the psychological effects of cortisol secretion in pediatric patients with Cushing disease. Continuation of this protocol will eventually lead to new, separate protocols that will address all aspects of diagnosis of pituitary tumors and their therapy in childhood. (ii)<TAB>Identifying the genetic components of pituitary oncogenesis; those will be investigated by (a) studying the inheritance pattern of pituitary tumors in childhood and their possible association with other conditions in the families of the patients, and (ii) collecting tumor tissues and examining their molecular genetics. As with the clinical studies, the present protocol may help generate ideas for future studies on the treatment and clinical follow up of pediatric patients with tumors of the pituitary gland and, thus, lead to the development of better therapeutic regimens for these neoplasms.


Description:

Study Description: This protocol aims to evaluate subjects with tumors of the hypothalamic pituitary unit to: identify genetic components of pituitary and hypothalamic oncogenesis, to develop new clinical studies for the recognition and therapy of pituitary tumors, and to investigate the psychological effects of cortisol secretion. Objectives: Primary Objective: To collect peripheral blood DNA samples and tumor tissues and examine the molecular genetics of the specimens, in an effort to elucidate developmental pathways leading to pituitary gland oncogenesis and/or other defects. Secondary Objectives: To serve as a screening protocol for future studies on the treatment and clinical follow up of our patients with pituitary tumors; it is our hope that the protocol will continue to be a vehicle for the development of more related clinical studies. To evaluate the cognitive, psychological, and patient-reported health status of mental and social well-being and symptoms of adrenal insufficiency associated with Cushing syndrome in children with this disease. Endpoints: Primary Endpoint: Molecular genetic testing, whole exome sequencing Secondary Endpoints: Pre-post treatment comparison of research variables related to pituitary/hypothalamic tumors and comorbidities. Cognitive, behavioral, psychological, and patient-reported outcomes


Recruitment information / eligibility

Status Recruiting
Enrollment 2000
Est. completion date
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 3 Years to 70 Years
Eligibility - INCLUSION CRITERIA: 1. Stated willingness to comply with all study procedures and availability for the duration of the study 2. Male or female, aged 3 years to 70 years 3. Evidence for the existence of a tumor of the hypothalamic-pituitary unit, as indicated by previously obtained imaging studies or biochemical investigation of the hypothalamohypophyseal function. 4. Family members (any age) of patients with a family history of tumors and who will agree to participate in the DNA/linkage analysis study. 5. Member of a kindred suspected of having an inherited form of pituitary neoplasia, as evidenced by results of a patient enrolled in this protocol. 6. Ability of subject or Legally Authorized Representative (LAR)) to understand and the willingness to sign a written informed consent document. EXCLUSION CRITERIA: 1. Pregnancy.

Study Design


Intervention

Procedure:
MRI

Tissue specimen collection


Locations

Country Name City State
United States National Institutes of Health Clinical Center Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Magiakou MA, Mastorakos G, Oldfield EH, Gomez MT, Doppman JL, Cutler GB Jr, Nieman LK, Chrousos GP. Cushing's syndrome in children and adolescents. Presentation, diagnosis, and therapy. N Engl J Med. 1994 Sep 8;331(10):629-36. doi: 10.1056/NEJM199409083311002. — View Citation

Stratakis CA, Carney JA, Lin JP, Papanicolaou DA, Karl M, Kastner DL, Pras E, Chrousos GP. Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2. J Clin Invest. 1996 Feb 1;97(3):699-705. doi: 10.1172/JCI118467. — View Citation

Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E, Leal LF, Caberg JH, Castermans E, Villa C, Dimopoulos A, Chittiboina P, Xekouki P, Shah N, Metzger D, Lysy PA, Ferrante E, Strebkova N, Mazerkina N, Zatelli MC, Lodish M, Horvath A, de Alexandre RB, Manning AD, Levy I, Keil MF, Sierra Mde L, Palmeira L, Coppieters W, Georges M, Naves LA, Jamar M, Bours V, Wu TJ, Choong CS, Bertherat J, Chanson P, Kamenicky P, Farrell WE, Barlier A, Quezado M, Bjelobaba I, Stojilkovic SS, Wess J, Costanzi S, Liu P, Lupski JR, Beckers A, Stratakis CA. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014 Dec 18;371(25):2363-74. doi: 10.1056/NEJMoa1408028. Epub 2014 Dec 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Molecular genetic testing, whole exome sequencing To collect peripheral blood DNA samples and tumor tissues and examine the molecular genetics of the specimens, in an effort to elucidate developmental pathways leading to pituitary gland oncogenesis and/or other defects. ongoing
Secondary To investigate the usefulness of a new MRI of the pituitary gland Comparison of MRI techniques to identify micro adenomas completed
Secondary To identify the clinical and genetic features of pituitary tumors by investigating their inheritance pattern and possible association with other conditions in the families of the patients, Genetic studies of pituitary and hypothalamic tumors or related disorders ongoing
Secondary To evaluate the cognitive, psychological, and patient-reported health status of mental and social well-being and symptoms of adrenal insufficiency associated with Cushing syndrome in children with this disease. Descriptive study of cognitive, psychological, and patient-reported health status of mental and social well-being associated with Cushing and after treatment ongoing
Secondary to collect peripheral blood DNA samples and tumor tissues and examine the molecular genetics of the specimens, in an effort to elucidate developmental pathways leading to pituitary gland oncogenesis and/or other defects Genetic studies of pituitary and hypothalamic tumors or related disorders ongoing
See also
  Status Clinical Trial Phase
Completed NCT02350153 - Cushing´s Disease Epidemiology in Sweden
Not yet recruiting NCT03297892 - Health Status of the Patients Followed for a Disease of Cushing in the Region Large-West of 1990 to 2015 N/A
Recruiting NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome Phase 1/Phase 2
Recruiting NCT03364803 - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Recruiting NCT03774446 - Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Phase 2
Completed NCT03080181 - Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Phase 4
Recruiting NCT03831958 - Long-Term Follow-Up of Survivors of Pediatric Cushing Disease
Completed NCT01331239 - Safety and Efficacy of LCI699 in Cushing's Disease Patients Phase 2
Completed NCT04201444 - Hair Cortisol and Cushing's Disease N/A
Completed NCT02233335 - The Factors Associated With the Recurrence in Patients With Cushing Disease N/A
Recruiting NCT04374721 - Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders N/A
Recruiting NCT03974789 - Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms
Completed NCT03621280 - Open-label Treatment in Cushing's Syndrome Phase 3
Not yet recruiting NCT05971758 - Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease Phase 2
Recruiting NCT04486859 - Postoperative Thrombosis Prevention in Patients With CD N/A
Completed NCT00171951 - Extension Study to Assess the Safety and Efficacy of Pasireotide in Participants With Cushing's Disease Phase 2